Zydus receives USFDA approval for Zituvimet™ XR tablets

Zydus Lifesciences has received final approval for its New Drug Application (NDA) from the United States Food and Drug Administration (USFDA) to market Zituvimet™ XR (sitagliptin and metformin hydrochloride) extended-release tablets.